Immunology - [Free Webinar] Closing the Loop in Allogeneic CAR-T Manufacturing: An Integrated Electroporation Workflow
View as a Web Page
News Medical
 
  Immunology Immunology logo  
  The latest immunology news from News Medical  
 

Critical Donor Selection Considerations for Immunology WorkflowsCritical Donor Selection Considerations for Immunology Workflows

Are you relying on the right criteria when selecting donors for cell therapy and immunology workflows? BioIVT’s VP of Scientific Affairs joins Labroots for a webinar discussing practical utilization of donor biology instead of demographics to drive better outcomes.

Learn More & Register
 
 
    [Free Webinar] Closing the Loop in Allogeneic CAR-T Manufacturing: An Integrated Electroporation Workflow[Free Webinar] Closing the Loop in Allogeneic CAR-T Manufacturing: An Integrated Electroporation Workflow
 
The development of allogeneic CAR-T therapies requires efficient, scalable manufacturing processes that reduce manual intervention and minimize open handling. In this webinar, we’ll explore the development of an integrated manufacturing workflow combining automated cell processing, gene editing, cell expansion, and final product processing.
Book your place
 
 
   Self-assembling antibody drugs successfully target multiple cancer receptorsSelf-assembling antibody drugs successfully target multiple cancer receptors
 
Modern anticancer medications that combine tumor-fighting drugs with proteins that specifically target cancer cells are a relatively new class of drug, often given to patients for whom standard chemotherapy has not worked.
 
 Specialized dendritic cells found to coordinate antitumor immunity
 
Specialized dendritic cells found to coordinate antitumor immunityResearchers at the Icahn School of Medicine at Mount Sinai have identified the immune cell that acts as the architect and coordinator of powerful immune hubs that form inside tumors and plays a key role in antitumor immunity.
 
 
 First-in-human trial tests safer T-cell therapy for pediatric brain cancers
 
First-in-human trial tests safer T-cell therapy for pediatric brain cancersResearchers report encouraging early results from a first-in-human clinical trial led by Children's National using a new T-cell immunotherapy for children and young adults with some of the deadliest brain tumors, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors.
 
 
 New anti-lipid antibodies could improve diagnosis of Lyme disease
 
New anti-lipid antibodies could improve diagnosis of Lyme diseaseLyme disease can be easiest to treat in its earliest stages, but current tests often miss infections during that critical window and cannot tell whether bacteria are still present or were cleared years ago.
 
 
 New HIV vaccine successfully generates broadly neutralizing antibodies in primates
 
New HIV vaccine successfully generates broadly neutralizing antibodies in primatesA new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists, and IAVI has the potential to protect humans from developing HIV infection and AIDS.
 
 
 Computationally designed antibody attacks previously untreatable KRAS cancer mutations
 
Computationally designed antibody attacks previously untreatable KRAS cancer mutationsAntibodies are like "guided missiles" that find and attack cancer cells, but cancer-causing mutations inside cells have remained a "blind spot" for treatment because antibodies cannot reach them.
 
 
 Children remain more vulnerable to influenza despite protective antibody levels
 
Children remain more vulnerable to influenza despite protective antibody levelsResearchers analyzing 1,518 South African household participants found that higher pre-season antibody titers were associated with lower infection risk for three of four influenza viruses studied. Children remained more susceptible after accounting for measured exposure and antibody titers, while younger children shed viral RNA longer than older adults.
 
 
 New antibody-specific AI framework accelerates discovery of therapeutic drugs
 
New antibody-specific AI framework accelerates discovery of therapeutic drugsDesigning an effective antibody drug is like searching for the right key in a warehouse of locks. Scientists may begin with millions-or even billions-of antibody candidates, but only a tiny fraction will recognize and bind tightly to the disease target.
 
 

How would you rate today's newsletter?

 
             
 
 
Google News Icon Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now.
 
Facebook X Instagram LinkedIn Vimeo
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd., NEO, 9 Charlotte St, Manchester, M1 4ET, UK

Manchester | Sydney

Copyright © 2000-2026